BPA
REGN icon

Beacon Pointe Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Beacon Pointe Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15M Buy
19,460
+7,396
+61% +$5.66M 0.08% 225
2025
Q4 		$9.31M Sell
12,064
-147
-1% -$99.8K 0.07% 270
2025
Q3 		$6.87M Sell
12,211
-7,256
-37% -$4.1M 0.06% 294
2025
Q2 		$10.2M Sell
19,467
-48
-0.2% -$26.8K 0.11% 175
2025
Q1 		$12.4M Sell
19,515
-161
-0.8% -$111K 0.14% 148
2024
Q4 		$14M Sell
19,676
-425
-2% -$357K 0.16% 136
2024
Q3 		$21.1M Sell
20,101
-2,169
-10% -$2.41M 0.24% 100
2024
Q2 		$23.4M Sell
22,270
-330
-1% -$320K 0.28% 77
2024
Q1 		$21.8M Sell
22,600
-186
-0.8% -$177K 0.24% 90
2023
Q4 		$20M Sell
22,786
-1,045
-4% -$861K 0.24% 102
2023
Q3 		$19.6M Buy
23,831
+1,259
+6% +$989K 0.24% 100
2023
Q2 		$16.2M Sell
22,572
-2,207
-9% -$1.7M 0.26% 91
2023
Q1 		$20.4M Sell
24,779
-7,144
-22% -$5.39M 0.35% 74
2022
Q4 		$23M Buy
31,923
+4,210
+15% +$3.11M 0.45% 54
2022
Q3 		$19.1M Sell
27,713
-338
-1% -$213K 0.43% 57
2022
Q2 		$16.6M Sell
28,051
-499
-2% -$324K 0.35% 71
2022
Q1 		$19.9M Buy
28,550
+3,603
+14% +$2.28M 0.27% 90
2021
Q4 		$15.8M Sell
24,947
-4,104
-14% -$2.52M 0.41% 58
2021
Q3 		$17.6M Buy
29,051
+21,898
+306% +$13.6M 0.43% 56
2021
Q2 		$4M Buy
+7,153
New +$3.62M 0.14% 144

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Beacon Pointe Advisors's REGN Position: Q1 2026 in Review

Beacon Pointe Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 61% in Q1 2026, buying an estimated $5.66M and bringing the position to 19,460 shares worth $15M. The position accounts for 0.08% of the portfolio, ranked #225.

Beacon Pointe Advisors first reported a position in REGN in Q2 2021 and has held it in 20 quarters since. The position peaked at $23.4M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Beacon Pointe Advisors held 19,460 shares of Regeneron Pharmaceuticals worth $15M as of Q1 2026.
  • Beacon Pointe Advisors bought 7,396 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $5.66M.
  • Regeneron Pharmaceuticals made up 0.08% of Beacon Pointe Advisors's portfolio in Q1 2026, its #225 holding.
  • Beacon Pointe Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Beacon Pointe Advisors's Regeneron Pharmaceuticals position peaked at $23.4M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.